gut microbiome News
-
Medbiome`s founders demonstrated that structurally similar compounds can have distinct effects on individual microbiomes
In a recent paper in Gut Microbes the founders of MedBiome reported the effects of berberine (BBR) and 16 structural analogs on seven individual gut microbiomes using our RapidAIM technology. This article clearly illustrates that the RapidAIM technology can distinguish the effects of structurally similar compounds on individual microbiomes. This is an important milestone when selecting and ...
-
Joint webinar of Thermo Fisher Scientific and Bio-Me on September 22nd with focus on how the PMP technology can support researchers and industry
On September 22nd Warren Flood, Ph.D. and COO of Bio-Me, will participate in a webinar organized together with Thermo Fisher Scientific with the title “Missing a piece of the puzzle? Factor in the gut microbiome”. There, he will present how our PMP platform, based on Thermo Fisher Scientific’s OpenArray qPCR technology, helps researchers and industry translating their gut ...
By Bio-Me
-
Symberix Co-Founder Gives Keynote Address at AACR Conference
Symberix co-founder Matthew Redinbo gave the keynote address at the AACR Microbiome, Viruses, and Cancer conference on Friday, February 21, 2020. The special conference covers the contribution of bacterial, viral, and fungal pathogens to the development of cancers, as well as the impact of the microbiome on cancer therapy. Dr. Redinbo’s keynote, titled “Molecular control of the gut ...
-
Microviable Therapeutics to enter into a contractual agreement with BCD Bioscience
Microviable Therapeutics SL (Gijón, Asturias, Spain), announced a contractual agreement with BCD Bioscience Inc. (California, USA) to work on microbial fermentation and novel prebiotics to modulate the human gut microbiome. Microviable expertise on gut microbiome research will enable to conveniently process microbiota samples for fermentation applications that coupled with BCD ...
-
Microvi and Nexilico Develop Powerful Computational Platform for Gut Microbiome funded by NIH
Under a National Institute of Health (NIH) grant awarded by the National Institute of General Medical Sciences (NIGMS), Microvi, Nexilico, and their research partners have developed a first-of-its-kind predictive computational platform focused on the gut microbiome and its interaction with therapeutics. The in silico platform reduces the cost and timeframe of drug development by reducing the ...
-
Bio-Me at 4th National Microbiota Conference
During the 4th Norwegian National Microbiota Conference to be held in Oslo, Norway on 9th November, Dr. Morten Isaksen, CEO of Bio-Me has been invited to present Bio-Me and its contribution to use of information from the gut microbiome in clinical settings. The Conference gathers different groups that work within the field of microbiome/microbiota related aspects in Norway. This field is ...
By Bio-Me
-
EnteroBiotix CEO featured on The Pharma Letter podcast talking about mastering the microbiome
Our Founder & CEO Dr James McIlroy was recently featured on The Pharma Letter podcast with Simon Wentworth discussing mastering the microbiome. James discusses how EnteroBiotix is developing its pipeline of highly diverse microbiome enhancing therapeutics through a unique approach to development and manufacturing, focussed on supply chain control and novel technologies. Listen here to ...
-
Husker scientists studying our ‘second brain’ - the gut microbiome
Using what they’ve learned in the laboratory, and the specialized strains of bacteria they developed, Benson and Hutkins, along with Nebraska animal scientist Tom Burkey and former Husker scientist Jens Walter, launched their own company to bring their research to the marketplace. Synbiotic Health will provide something novel and clinically proven — a product that mixes beneficial ...
-
EnteroBiotix completes new manufacturing facility focused on gut microbiome therapies
EnteroBiotix, a Scottish biopharma focused on making gut microbiome therapies, said construction of its new manufacturing, lab and office facility has been completed. Located at the Strathclyde Business Park in Bellshill, the 20,000-square-foot facility is designed to meet regulatory biologics requirements and product analysis while providing the company end-to-end control of its supply chain, ...
-
Evolve BioSystems, Inc. Announces Collaboration with Janssen to Study the Impact of B. infantis EVC001 in the Reduction of Atopic Dermatitis
Evolve BioSystems, Inc., a global leader dedicated to improving human health through the gut microbiome, today announced a collaboration with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to conduct a clinical study in children at risk for developing atopic dermatitis. The study will assess the effects of introducing a specific gut ...
-
New Study: Infant Gut Health Must Focus on Microbiome Function, Not Diversity
The concepts of ecology, conservation, and restoration typically conjure images of natural woodlands, water systems and air quality. However, a new peer-reviewed perspective by Evolve BioSystems is taking a page from ecology playbooks in an effort to assist neonatologists and other pediatric health care professionals in assessing the state of the infant gut microbiome, which plays a significant ...
-
EnteroBiotix Raises over $21m in Series A Financing to Advance its Microbiome Drug Pipeline
EnteroBiotix, a biopharmaceutical company developing novel high-diversity microbial therapeutics that enhance the gut microbiome and target multiple indications, today announced the final closing of its oversubscribed USD $21.5 million (UK £15.5m) Series A financing. The proceeds will be used to further advance the company’s microbiome drug pipeline and underpin its product ...
-
Symberix Awarded $2 Million from National Institutes of Health to Support Lead Program
Symberix has been awarded the Phase II portion of a Small Business Innovation Research (SBIR) Fast-Track grant from the National Institutes of Health (NIH). The NIH Fast-Track application process expedites award decisions and funding of Phase II applications that have a high potential for commercialization by allowing Phase I and Phase II grant applications to be submitted and reviewed together. ...
-
MetaboGen and BioGaia initiates program for microbiome restoration
Today, MetaboGen and BioGaia have agreed to initiate a new development program addressing restoration of the microbiome after antibiotic treatment. The program will combine expertise and experience from both companies and is part of the long-term relationship between MetaboGen and BioGaia. For background, read more here: The microbiome has gained considerable interest as modulators of health ...
By Metabogen AB
-
Agilent Technologies Presents Thought Leader Award to Human Microbiome Expert Jeffrey Gordon
Agilent Technologies Inc. (NYSE: A) today announced that Dr. Jeffrey Gordon has received an Agilent Thought Leader Award in support of his pioneering research into the mutually beneficial relationship between the human body and the tens of trillions of microbes that inhabit the gastrointestinal tract. Dr. Gordon directs the Center for Genome Sciences and Systems Biology at Washington University ...
-
Official Opening of Service Laboratory
Bio-Me, a pioneer in rapid gut microbiome analysis is announcing the opening of its gut microbiome analysis service laboratory. This will enable the Research & Development departments worldwide to access their Precision Microbiome Profiling (PMP™) platform. The service laboratory is located at the Oslo’s Science Park’s premier lab sharing facility, the ShareLab. The lab ...
By Bio-Me
-
Notitia Biotechnologies receives approval from FDA for phase 2A clinical trial in diabetic & prediabetic patients
Notitia Biotechnologies Company has received the Investigational New Drug (IND) approval from the FDA for NBT-NM108, a proprietary formula designed to support the Foundation Guild bacteria in the patient's gut microbiome. The FDA has allowed Notitia to test the drug as a treatment for COVID-19 in patients with type 2 diabetes and prediabetes. Notitia has secured funding for a Phase 2a ...
-
Symberix Awarded Multiple Grants from National Institutes of Health to Expand Platform of Microbiome-Targeted Drugs
Symberix, a preclinical stage company dedicated to the development of novel pharmaceutical treatments for lower gastrointestinal (GI) disorders, has been awarded two Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH). The two SBIR grants collectively totaling over $1.5 million are awarded by the NIH’s National Center for Advancing Translational ...
-
Testing of a Drug Panel for effects on the gut Microbiome using RapidAIM
MedBiome’s founders reported in Microbiome the development of the RapidAIM platform to screen compounds against individual microbiomes in vitro. They tested 43 compounds (including 4 antibiotics) against 5 individual microbiomes using the RapidAIM technology. The RapidAIM workflow provides insights into microbiome absolute abundance and functional responses to drugs. ...
-
New Preclinical Research Published in Nature Highlights an Active Role by Microbiome-Derived Metabolites in Brain Function and Anxiety-like Behavior
Study adds to growing evidence for how gut microbiome impacts Central Nervous System (CNS) function and behavior in mice Research offers valuable mechanistic insights for understanding the potential role of microbial metabolites in neurodevelopmental disorders Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you